Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities.

Saved in:
Bibliographic Details
Title: Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities.
Authors: Lozac'hmeur A; Tempus AI Inc., Chicago, IL, USA., Danek T; Tempus AI Inc., Chicago, IL, USA., Yang Q; Tempus AI Inc., Chicago, IL, USA., Rosasco MG; Tempus AI Inc., Chicago, IL, USA., Welch JS; A2 Biotherapeutics, Agoura Hills, CA, USA., Go WY; A2 Biotherapeutics, Agoura Hills, CA, USA., Ng EW; A2 Biotherapeutics, Agoura Hills, CA, USA., Mardiros A; A2 Biotherapeutics, Agoura Hills, CA, USA., Maloney DG; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Garon EB; David Geffen School of Medicine, University of California, Los Angeles, CA, USA., Kirtane K; Moffitt Cancer Center, Tampa, FL, USA., Simeone DM; Moores Cancer Center, UC San Diego Health, San Diego, CA, USA., Molina JR; Mayo Clinic, Rochester, MN, USA., Salahudeen AA; University of Illinois at Chicago College of Medicine, Departments of Medicine, Biochemistry & Molecular Genetics, Chicago, IL, USA., Stein MM; Tempus AI Inc., Chicago, IL, USA. publications@tempus.com., Hecht JR; David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Source: NPJ precision oncology [NPJ Precis Oncol] 2024 Aug 05; Vol. 8 (1), pp. 174. Date of Electronic Publication: 2024 Aug 05.
Publication Type: Journal Article
Journal Info: Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2397-768X
DOI:10.1038/s41698-024-00665-z